Jazz Pharmaceuticals Announces Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
BMO Capital Cuts Price Target on Jazz Pharmaceuticals (JAZZ) to $192
November 9, 2016 8:35 AM ESTBMO Capital maintained an Outperform rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $192.00 (from $195.00), following the company's 3Q earnings report. Revenue was reported at $374mn, missing the consensus estimate of $389mn. While revenue fell short, it was mainly due... More
Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 4c; Guides In-Line
November 8, 2016 4:09 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $2.57, $0.04 worse than the analyst estimate of $2.61. Revenue for the quarter came in at $374 million versus the consensus estimate of $389.23 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2016 EPS of $9.90-$10.30, versus the consensus of $10.06.... More
